We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Factor Xa-Based Antithrombin Assay Evaluated

By LabMedica International staff writers
Posted on 15 Nov 2011
A recently introduced antithrombin assay based on Factor Xa (FXa) has been evaluated on four different analyzers. More...


The INNOVANCE Antithrombin test is a new FXa-based chromogenic assay for automated quantification of functionally active anti-thrombin (AT) on coagulation analyzers.

Scientists working at Siemens Healthcare Diagnostic Products GmbH (Marburg, Germany) collaborated with investigators from the UK, Italy and another institution in Germany. They used clinical surplus plasma samples from 225 patients and 151 apparently healthy individuals from four different study sites to assay antithrombin.

The Siemens' INNOVANCE Antithrombin assay demonstrated on all analyzers repeatability coefficients of variation (CVs) ≤ 3.2% and within-device and between-run CVs ≤ 6.9%. The reference intervals of all analyzers are comparable with 2.5th percentiles between 80% and 85% of normal. The Siemens' INNOVANCE Antithrombin and the Factor IIa-based BerichromAT III (A) methods demonstrated good concordance with very high correlation coefficients.

The INNOVANCE Antithrombin method exhibited an excellent comparability with the STA Antithrombin III assay (Diagnostica Stago; Asnières sur Seine, France) and an acceptable comparability with the Coamatic LR Antithrombin assay (Instrumentation Laboratory, Bedford, MA, USA). The 31 patients with congenital deficiency were identified with all assays except for the patients carrying the P41L heparin-binding site mutation, which was only identified with the INNOVANCE Antithrombin and the STA Antithrombin III methods.

The authors concluded that this multicenter study demonstrates that the INNOVANCE antithrombin assay is precise and reliable to aid in the diagnosis of antithrombin deficiency. The advantages of this assay compared to the other methods were the higher sensitivity for heparin-binding site mutations, the liquid ready-to-use reagents, and the absence of interference by direct thrombin inhibitors. The study was published in October 2011, in the journal International Journal of Laboratory Hematology.

Related Links:
Siemens Healthcare Diagnostic Products
Diagnostica Stago
Instrumentation Laboratory


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.